Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (NCT05703971)
A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).
Who can join: Review the eligibility criteria below.
Location: Rocky Mountain Cancer Centers, LLP — Lone Tree, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- Rocky Mountain Cancer Centers, LLP — Lone Tree, Colorado
- Washington University School of Medicine - Siteman Cancer Center — St Louis, Missouri
- Gabrail Cancer Center Research — Canton, Ohio
- Oncology_Hematology Care Clinical Trials, LLC — Cincinnati, Ohio
- Oncology_Hematology Care Clinical Trials, LLC — Cincinnati, Ohio
- Oncology_Hematology Care Clinical Trials, LLC — Cincinnati, Ohio
- Oncology_Hematology Care Clinical Trials, LLC — Cincinnati, Ohio
- Oncology_Hematology Care Clinical Trials, LLC — Fairfield, Ohio
- Willamette Valley Cancer Institute (Oregon) — Eugene, Oregon
- Northwest Cancer Specialists, P.C. — Portland, Oregon
- Providence Cancer Institute — Portland, Oregon
- Northwest Cancer Specialists, P.C. — Portland, Oregon
- Northwest Cancer Specialists, P.C. — Tigard, Oregon
- Texas Oncology - DFW — Dallas, Texas
- Texas Oncology - Northeast Texas — Tyler, Texas
- Virginia Cancer Specialists, PC — Fairfax, Virginia
- Northwest Cancer Specialists, P.C. — Vancouver, Washington
📞 Contact the Study Coordinator
Phone: 1-877-774-GNPX
Email: kcombs@genprex.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Small Cell Lung Cancer Extensive Stage
- Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer — Tampa, Florida
- DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer — Tampa, Florida
- Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) — Dallas, Texas
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) — Santa Rosa, California
Explore by condition: All Small Cell Lung Cancer Extensive Stage clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.